Financial Performance - The company's operating revenue for the first half of 2023 was ¥648,800,511.90, representing a 45.24% increase compared to ¥446,711,611.07 in the same period last year[23]. - The net profit attributable to shareholders for the first half of 2023 was ¥74,270,290.76, up 43.88% from ¥51,621,096.01 in the previous year[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥72,189,143.96, reflecting a 50.20% increase from ¥48,062,950.29 year-on-year[23]. - The basic earnings per share for the first half of 2023 was ¥0.27, a 42.11% increase compared to ¥0.19 in the same period last year[23]. - The total assets at the end of the reporting period were ¥3,308,077,242.39, which is a 5.58% increase from ¥3,133,329,649.02 at the end of the previous year[23]. - The net assets attributable to shareholders at the end of the reporting period were ¥2,045,342,958.33, up 3.63% from ¥1,973,785,133.36 at the end of the previous year[23]. - The net cash flow from operating activities was -¥71,335,220.71, a decline of 98.17% compared to -¥35,997,732.88 in the same period last year[23]. - The weighted average return on net assets was 3.69%, an increase of 0.93% from 2.76% in the previous year[23]. Strategic Focus and Development - The company has established a dual-driven development strategy focusing on smart manufacturing and rehabilitation medical equipment, aiming to become a service provider in the health sector[32]. - The company emphasizes the importance of risk awareness regarding forward-looking statements in the report[4]. - The company is positioned to benefit from favorable policies promoting the development of smart manufacturing in the pharmaceutical industry, particularly during the "14th Five-Year Plan" period[35]. - The company aims to leverage technologies such as the internet, robotics, and artificial intelligence to expand its presence in the health sector, focusing on integrated smart manufacturing solutions[105]. - The company plans to enhance its R&D capabilities and expand its product line to address increasing market competition in the pharmaceutical and rehabilitation medical equipment sectors[133]. Product and Market Expansion - The smart manufacturing business primarily serves pharmaceutical and bioproduct manufacturing companies, providing comprehensive smart manufacturing solutions[33]. - The company focuses on expanding its smart manufacturing business by broadening its service areas to include chemical synthesis, traditional Chinese medicine extraction, and biopharmaceuticals, which are expected to drive new growth[45][46]. - The rehabilitation medical device sector is experiencing rapid growth, with China's rehabilitation demand reaching 460 million people in 2019, driven by an aging population and increasing prevalence of neurological diseases[52]. - The company has developed specialized solutions for six major fields, including pain rehabilitation and neurological rehabilitation, providing targeted "one-stop" solutions for common diseases[62]. - The company is actively expanding its product offerings, with several devices registered in the last few years, indicating a commitment to innovation and market growth[88]. Financial Management and Investments - The company has a robust supplier assessment system to ensure timely procurement of raw materials based on sales forecasts and production plans[72]. - The production model for rehabilitation medical devices is based on inventory production, allowing for timely delivery upon customer orders[74]. - The company has committed a total of 30,876.72 million CNY for investment projects, with 29,519.1 million CNY already invested, achieving an investment progress of 95.6%[122]. - The company has temporarily supplemented working capital with 3.9 million CNY from idle raised funds, with a usage period not exceeding 12 months from the board approval date[124]. - The company reported a significant decrease in investment, with a 100% drop from CNY 106,000,000.00 in the previous year to CNY 0.00 in the current period[118]. Regulatory Compliance and Corporate Governance - The company has established a research and development risk control system to mitigate risks associated with long development cycles, high technical difficulty, and significant funding requirements in the pharmaceutical and rehabilitation medical equipment sectors[134]. - The company has not engaged in any derivative investments during the reporting period, indicating a conservative investment strategy[128]. - The company has not reported any overdue amounts or impairment risks related to its entrusted financial management activities[127]. - The company has not experienced any significant changes in the feasibility of its investment projects during the reporting period[125]. - The company has committed to fulfilling its corporate social responsibilities, ensuring compliance with laws and regulations, and maintaining investor rights[149]. Market Presence and Brand Recognition - The company has established a strong market presence, with its products being used in over 5,000 medical institutions domestically and exported to over 30 countries[59]. - The brand "Chengyitong" has gained significant recognition in the industry, providing a solid foundation for market share expansion[103]. - The company is expanding its market presence in Europe, with plans to enter three new countries by the end of the fiscal year[92]. - The company is actively promoting its brand through academic activities, enhancing its reputation and influence in the rehabilitation sector[69]. Future Outlook - The company provided guidance for the next quarter, projecting revenue growth of 20% to $180 million[93]. - Future strategies include increasing investment in digital marketing to boost user engagement and brand awareness[93]. - The company anticipates growth in the rehabilitation market, driven by an increasing demand for innovative medical devices and therapies[89]. - The company aims to enhance its market presence through the introduction of innovative rehabilitation devices, targeting specific patient needs such as swallowing dysfunction and limb strength deficiency[89].

证券代码：300430 证券简称：诚益通 公告编号：2023-047 北京诚益通控制工程科技股份有限公司 第五届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 会议由公司董事长梁凯先生主持，经参会董事认真审议，形成决议如下： 一、审议通过《关于公司<2023 年半年度报告>及其摘要的议案》 经审议，董事会一致认为：公司《2023 年半年度报告》及其摘要真实反映 了公司 2023 年上半年的财务状况和经营成果，符合法律、行政法规、中国证监 会及深圳证券交易所的相关规定，报告内容真实、准确，完整，不存在任何虚假 记载、误导性陈述或者重大遗漏。同意公司对外报出。 具体内容详见同日披露在中国证监会指定创业板信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）上发布的公司《2023 年半年度报告》全文及摘 要。 表决结果：同意票 9 票，反对票 0 票，弃权票 0 票。 二、审议通过《关于公司<2023 年半年度募集资金存放与使用情况专项报告> 的议案》 经审议，董事会认为该专项报告的编制符合相关法律、法规的规定，真实、 ...

北京诚益通控制工程科技股份有限公司 募集资金存放与实际使用情况的专项报告 北京诚益通控制工程科技股份有限公司关于 2023 年 半年度募集资金存放与实际使用情况的专项报告 一、募集资金基本情况 经中国证券监督管理委员会《关于核准北京诚益通控制工程科技股份有限公 司向罗院龙等发行股份购买资产并募集配套资金的批复》（证监许可[2017]127 号） 核准，公司向广州龙之杰科技有限公司（以下简称"广州龙之杰"）、北京诚益 通博日鸿智能装备技术有限公司（原名"北京博日鸿科技发展有限公司"，以下 简称"北京博日鸿"）原股东发行股份及支付现金购买其持有的广州龙之杰、北 京博日鸿 100%股权，并向特定投资者发行人民币普通股 6,577,900 股，发行价格 46.94 元/股，募集资金总额人民币 308,766,626.00 元，扣除承销费、律师费、资 产评估费、审计费等发行费用 14,141,672.88 元后，剔除承销费用对应的增值税 566,037.74 元，实际募集资金净额为 295,190,990.86 元。上述资金到位情况已经 大信会计师事务所（特殊普通合伙）验证，并出具了大信验字[2017]第 2-0002 ...

证券代码：300430 证券简称：诚益通 公告编号：2023-048 北京诚益通控制工程科技股份有限公司 第五届监事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京诚益通控制工程科技股份有限公司（以下简称"公司"）第五届监事会 第二次会议通知已于 2023 年 8 月 14 日以电子邮件、专人送达等方式发出，并于 2023 年 8 月 24 日在公司召开。本次会议应出席监事 3 人，实际参会监事 3 人， 由监事会主席刘泽君先生主持。会议的召开符合法律、行政法规、部门规章及《公 司章程》的规定，合法有效。 经与会监事认真审议后，通过以下决议： 一、审议通过《关于公司<2023 年半年度报告>及其摘要的议案》 经审议，监事会认为，《2023 年半年度报告》及其摘要的编制和审议程序 符合法律、行政法规及监管部门规定，《2023 年半年度报告》及其摘要内容真 实、准确、完整地反映了本报告期公司的财务状况和经营成果，不存在虚假记载、 误导性陈述或重大遗漏。 二、审议通过《关于公司<2023 年半年度募集资金存放与使用情况专项报告> 的议案》 ...

证券代码：300430 证券简称：诚益通 公告编号：2023-045 北京诚益通控制工程科技股份有限公司 关于子公司担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、融资情况概述 北京诚益通控制工程科技股份有限公司（以下简称"公司"）于 2023 年 4 月 26 日召开了第四届董事会第二十次会议，会议审议通过了《关于公司及子公 司、孙公司申请银行综合授信及项目贷款额度的议案》、《关于为公司及子公司、 孙公司申请综合授信及项目贷款提供担保的议案》（公告编号：2023-017、018）， 同意公司、子公司及合并报表范围内的子公司、孙公司向银行及其他金融机构申 请合计额度不超过人民币 12.30 亿元的授信等业务，在授权期限内额度可循环使 用，担保总额合计不超过上述金额。上述议案同时由 2023 年 5 月 17 日召开的 2022 年度股东大会审议通过。 二、融资进展情况 近期，公司的全资子公司广州龙之杰科技有限公司（以下简称"龙之杰"） 与中国工商银行股份有限公司广州新塘支行（以下简称"工商银行广州新塘支 行"）签署《最高额抵押合同》，龙之杰 ...

3、公司目前和以后，还有哪些利润增长点？有什么具体有 效的保障措施？ 证券代码： 300430 证券简称：诚益通 北京诚益通控制工程科技股份有限公司 投资者关系活动记录表 | 投资者关系活动 | 分析师会议 □特定对象调研 □ | | --- | --- | | 类别 | □ 媒体采访 √ 业绩说明会 | | | □ 新闻发布会 □ 路演活动 | | | □ 现场参观 | | | 其他 （请文字说明其他活动内容） □ | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 年 月 日 (周二) 下午 2023 5 9 15:00~17:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待人 | 1、董事长、总经理梁凯 | | 员姓名 | 2、董事、副总经理、董事会秘书邱义鹏 | | | 3、财务总监卢振华 | | | 4、独立董事王福清 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： 1、怎么看待中药发展中贵司产生的机遇？ ...

Financial Performance - The company's revenue for Q1 2023 was CNY 245,247,004.70, representing a 19.88% increase compared to CNY 204,574,781.39 in the same period last year[5]. - Net profit attributable to shareholders for Q1 2023 was CNY 22,352,280.04, up 26.08% from CNY 17,728,313.32 in the previous year[5]. - The basic earnings per share for Q1 2023 increased by 33.33% to CNY 0.08, compared to CNY 0.06 in the same period last year[5]. - Total operating revenue for Q1 2023 reached CNY 245,247,004.70, an increase of 19.87% compared to CNY 204,574,781.39 in Q1 2022[28]. - Net profit for Q1 2023 was CNY 21,550,059.60, representing a 23.57% increase from CNY 17,487,664.35 in Q1 2022[29]. - Earnings per share for Q1 2023 were CNY 0.08, compared to CNY 0.06 in Q1 2022[30]. - The company reported a total comprehensive income of CNY 21,784,827.74 for Q1 2023, compared to CNY 18,046,499.43 in Q1 2022[30]. Cash Flow and Financial Position - The net cash flow from operating activities improved by 27.46%, with a net outflow of CNY 35,211,247.10 compared to CNY 48,540,611.39 in the previous year[5]. - Cash inflow from operating activities was CNY 301,307,142.59, an increase from CNY 218,424,156.89 in the previous year[32]. - The net cash flow from operating activities was -35,211,247.10 CNY, an improvement from -48,540,611.39 CNY in the previous year, indicating a 27.8% reduction in cash outflow[33]. - Total cash inflow from investment activities was 41,339,106.20 CNY, compared to 49,706,965.95 CNY in the same period last year, reflecting a decrease of 16.5%[33]. - The net cash flow from financing activities was 74,467,746.63 CNY, a significant increase from -27,458,523.28 CNY in the previous year, showing a turnaround in financing strategy[33]. - The total cash and cash equivalents at the end of the period amounted to 32,231,408.88 CNY, up from 5,036,632.24 CNY at the beginning of the period, representing a net increase of 27,194,776.64 CNY[33]. - The company received 150,920,000.00 CNY from borrowings, a substantial increase from 41,304,531.30 CNY in the same quarter last year, indicating a shift in financing approach[33]. Assets and Liabilities - Total assets at the end of Q1 2023 were CNY 3,220,463,446.78, reflecting a 2.78% increase from CNY 3,133,329,649.02 at the end of the previous year[5]. - The total liabilities as of Q1 2023 amounted to CNY 1,204,086,046.17, up from CNY 1,139,602,540.86 in Q1 2022[26]. - Total current liabilities rose to CNY 1,048,428,504.30 from CNY 994,311,017.32, reflecting an increase of about 5.45%[25]. - The total non-current assets remained relatively stable at CNY 1,534,400,490.34 compared to CNY 1,534,167,382.62 at the beginning of the year[25]. - The company has a total of 1,686,062,956.44 in current assets, up from 1,599,162,266.40, indicating a growth of approximately 5.42%[24]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 9,275[19]. - The largest shareholder, Beijing Liweit Investment Co., Ltd., holds 18.74% of the shares, with 30,425,170 shares pledged[20]. - The company reported a total of 16,433,248 shares under lock-up agreements, with 322,945 shares released during the period[22]. - The company plans to unlock shares for certain executives on specified dates, with the majority set for December 26, 2023, and January 1, 2024[22]. Expenses and Costs - Total operating costs for Q1 2023 were CNY 223,378,190.76, up 16.54% from CNY 191,640,292.73 in the same period last year[28]. - Research and development expenses for Q1 2023 totaled CNY 13,719,598.74, a decrease of 11.21% from CNY 15,451,339.53 in Q1 2022[29]. - Financial expenses increased to CNY 6,668,287.60 in Q1 2023, compared to CNY 2,889,822.86 in the same period last year[29]. - The company paid 52,527,726.79 CNY in employee-related cash payments, slightly down from 53,250,891.55 CNY in the previous year[33]. - Cash paid for taxes was 28,443,318.52 CNY, which is a significant increase from 12,378,373.40 CNY year-over-year, indicating a rise in tax obligations[33]. Other Income and Financial Changes - Other income grew by 46.20% year-on-year, mainly attributed to an increase in software tax refunds[15]. - The company reported a significant increase of 170.88% in non-operating income, largely due to increased policy subsidies[18]. - The impact of exchange rate changes on cash and cash equivalents was -655,757.93 CNY, compared to -409,357.25 CNY in the previous year[33]. - The company did not conduct an audit for the first quarter report[34].

Financial Performance - The company's operating revenue for 2022 was approximately ¥974.45 million, representing a 6.47% increase compared to ¥915.24 million in 2021[20]. - The net profit attributable to shareholders for 2022 was approximately ¥124.72 million, an increase of 21.32% from ¥102.80 million in 2021[20]. - The net profit after deducting non-recurring gains and losses was approximately ¥113.73 million, up 28.40% from ¥88.57 million in 2021[20]. - The basic earnings per share for 2022 was ¥0.46, a 21.05% increase from ¥0.38 in 2021[20]. - The total assets at the end of 2022 were approximately ¥3.13 billion, an increase of 8.87% from ¥2.88 billion at the end of 2021[20]. - The net assets attributable to shareholders at the end of 2022 were approximately ¥1.97 billion, a 7.14% increase from ¥1.84 billion at the end of 2021[20]. - The net cash flow from operating activities for 2022 was approximately ¥29.60 million, a decrease of 63.52% from ¥81.14 million in 2021[20]. - The weighted average return on net assets for 2022 was 5.97%, up from 4.89% in 2021[20]. Revenue Breakdown - The company reported a total revenue of approximately CNY 1.01 billion for the year, with quarterly revenues increasing from CNY 204.57 million in Q1 to CNY 279.35 million in Q4, representing a growth of 36.5% from Q1 to Q4[23]. - The smart manufacturing segment generated revenue of 703.12 million yuan, accounting for 72% of total revenue, with a year-on-year growth of 1.53%[86]. - The rehabilitation medical equipment segment reported revenue of 271.32 million yuan, contributing 28% to total revenue, and grew by 21.83% year-on-year[91]. - The company signed new orders exceeding 180 million yuan in the chemical synthesis business, marking an increase of over 83% year-on-year[87]. Research and Development - R&D investment reached over 28 million yuan in 2022, a 28% increase from the previous year, with 129 R&D personnel, up 37%[92]. - The company increased its R&D personnel from 306 in 2021 to 375 in 2022, representing a growth of 22.55%[118]. - The proportion of R&D personnel in the total workforce rose from 19.96% in 2021 to 22.52% in 2022, an increase of 2.56%[118]. - R&D investment amounted to ¥63,664,136.29 in 2022, up from ¥54,589,686.28 in 2021, reflecting a year-over-year increase of 16.67%[119]. - The R&D expenditure as a percentage of operating revenue was 6.53% in 2022, compared to 5.96% in 2021[119]. Market Expansion and Strategy - The company plans to expand its market coverage to Shandong, Sichuan, and Hebei provinces, building on its success in six major provinces[93]. - The company is actively expanding its distribution channels to grassroots medical institutions, aiming to leverage channel exclusivity for competitive advantage[71]. - The company aims to enhance its market position through strategic expansions and technological innovations in the pharmaceutical manufacturing sector, aligning with national policies promoting industry upgrades[36]. - The company plans to implement a new marketing strategy that includes digital channels, aiming for a 50% increase in online sales[133]. Product Development and Innovation - The company has developed a complete product line in rehabilitation medical devices, covering rehabilitation assessment, training, and physical therapy, making it one of the most comprehensive providers in the domestic market[65]. - The company is focusing on creating specialized rehabilitation solutions that address specific disease issues, enhancing its competitive edge in the rehabilitation market[66]. - The company is committed to expanding its product series and market share through innovative research and development initiatives[112]. - The company has developed a range of medical devices, including the Spasm Electromyostimulation Therapy Device and the Neuromuscular Electrical Stimulator, with approval dates ranging from 2015 to 2022[123]. Governance and Management - The company has a strong governance structure with multiple independent directors, enhancing oversight and strategic direction[9]. - The management team is stable and experienced, contributing to the company's long-term development and market competitiveness[83]. - The board of directors includes members with significant experience in the pharmaceutical and engineering sectors, contributing to strategic decision-making[14]. - The company emphasizes strict compliance with information disclosure regulations, ensuring accurate and timely information for investors[178]. Challenges and Risks - The company has faced uncertainties regarding its ability to continue as a going concern, as indicated by negative net profits over the last three accounting years[21]. - The company acknowledges risks in technology R&D and new product development, including potential deviations in R&D direction and high costs, and has established a risk control system for R&D projects[166]. - The company faces intensified market competition as downstream industry clients demand higher quality products, prompting the need for brand leverage and capital market resources to adapt to market changes[165].

（问题征集专题页面二维码） 特此公告。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京诚益通控制工程科技股份有限公司（以下简称"公司"）将于 2023 年 5 月 9 日（星期二）15:00-17:00 在全景网举办 2022 年度网上业绩说明会。本次 年度业绩说明会将采用网络远程方式举行，投资者可登录"全景•投资者关系互 动平台"（https://rs.p5w.net）参与本次年度业绩说明会。 参加本次年度业绩说明会的人员有：公司董事长、总经理梁凯先生，董事、 董事会秘书、副总经理邱义鹏先生，财务总监卢振华先生，独立董事王福清先生。 为充分尊重投资者，提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 5 月 5 日（星期五）16:00 前访问 http://ir.p5w.net/zj/，或扫描下方二维码， 进入问题征集专题页面。公司将在 2022 年度业绩说明会上，对投资者普遍关注 的问题进行回答。 欢迎广大投资者积极参与本次网上说明会。 证券代码：300430 证券简 ...

证券代码：300430 证券简称：诚益通 北京诚益通控制工程科技股份有限公司 投资者关系活动记录表 编号：20150529 | --- | --- | --- | |---------------------------|------------------------------|--------------------------------------------------------| | | | | | | ■ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活 | □ 新闻发布会 □路演活动 | | | 动类别 | □ 现场参观 | | | | □其他 | | | 参与单位及人 | 诺安基金罗春蕾、兴业证券李鸣 | | | 员姓名 | | | | 时间 | 2015 年 5 月 29 | 日 | | 地点 | 北京市海淀区丰慧中路 | 7 号新材料创业大厦 B 座 8 层会议室 | | 上市公司接待 | 董事会秘书：刘棣 | | | 人员姓名 | | | | 投资者关系活 动主要内容介 | 1 | 、诚益通公司与楚天、千山、东富龙、迦南等都是服务于医 ...